STOCK TITAN
  1. Home
  2. News
  3. CVRX

CVRx Inc - CVRX STOCK NEWS

Welcome to our dedicated news page for CVRx (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on CVRx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CVRx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CVRx's position in the market.

News
CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
Rhea-AI Summary
CVRx, Inc. (NASDAQ: CVRX) will release its first quarter 2024 financial and operating results on April 30th, 2024, followed by a conference call to discuss the results. The company focuses on developing, manufacturing, and commercializing Barostim™, an innovative neuromodulation device for cardiovascular diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.09%
Tags
conferences earnings
-
News
CVRx announces availability of additional data supporting long-term benefits of Barostim
Rhea-AI Summary
CVRx announces availability of additional data supporting long-term benefits of Barostim, highlighting sustained symptomatic improvements in heart failure patients with reduced ejection fraction. The data from the BeAT-HF trial published in the European Journal of Heart Failure and presented at THT conference show a reduction in heart failure interventions and improved quality of life for patients receiving Barostim.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
none
-
News
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
Rhea-AI Summary
CVRx, Inc. (NASDAQ: CVRX) appoints Kevin Hykes as the new President and CEO, effective February 12, following Nadim Yared's retirement. Hykes brings 30 years of experience in the medical device industry and has a deep understanding of CVRx, having served on the Company’s Board of Directors since December 2022. He has a proven track record of success in driving the adoption of medical devices and has received an inducement grant of 360,000 shares of the Company’s common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
management
News
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Rhea-AI Summary
CVRx, Inc. announced its financial and operating results for the fourth quarter and full year of 2023, with total revenue for the fourth quarter of 2023 being $11.3 million, an increase of 58% over the prior year quarter. U.S. Heart Failure (HF) revenue for the fourth quarter of 2023 was $10.2 million compared to $6.0 million in the prior year quarter, an increase of 70% over the prior year quarter. Total revenue for 2023 was $39.3 million, an increase of 75% over the prior year. Active implanting centers for 2023 increased to 178, a 68% increase since December 31, 2022. President and CEO Nadim Yared plans to retire upon the completion of a deliberate succession process and the appointment of a successor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.75%
Tags
earnings
-
News
CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024
Rhea-AI Summary
CVRx, Inc. (NASDAQ: CVRX) plans to release fourth quarter 2023 financial and operating results on January 25th, 2024. The company is a commercial-stage medical device company focused on developing, manufacturing, and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases. A conference call to review the results will be hosted at 4:30pm Eastern Time the same day, with a live webcast available on the investor relations page of the Company’s website at ir.cvrx.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
conferences earnings
-
News
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
Rhea-AI Summary
CVRx, Inc. (NASDAQ: CVRX) expects fourth-quarter revenue to be $11.2 to $11.3 million, representing 56% to 58% growth. Full-year revenue is projected to be $39.2 to $39.3 million, reflecting 74% to 75% growth. President and CEO Nadim Yared plans to retire upon the appointment of a successor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.34%
Tags
earnings
News
CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
CVRx, Inc. (CVRX) to Present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
conferences
-
News
CVRx receives FDA approval for expanded labeling of Barostim
Rhea-AI Summary
CVRx, Inc. (NASDAQ: CVRX) announces FDA approval of revised Instructions For Use for Barostim based on long-term BeAT-HF data. U.S. annual market opportunity for Barostim increases to $2.2 billion, or 76,000 new patients, representing a 60% increase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.21%
Tags
fda approval
-
News
CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
CVRx, Inc. (NASDAQ: CVRX) to Present at 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
News
CMS Increases Outpatient Payment for Barostim Procedure
Rhea-AI Summary
CVRx, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure to New Technology APC 1580 in the 2024 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. The new payment amount is $45,000, effective from January 1, 2024. This reassignment is expected to increase access to the therapy for Medicare patients with heart failure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.3%
Tags
none
Stock CVRX logo
CVRx Inc

Nasdaq:CVRX

CVRX Rankings

#3361 Ranked by Market Cap
#652 Ranked by Stock Gains
N/A Ranked by Dividends

CVRX Stock Data

360.58M
10.98M
9.86%
77.66%
3.97%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Minneapolis

About CVRX

cvrx is a private company located in minneapolis, minnesota. the company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. the barostim neo™ uses cvrx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. the barostim neo can be adjusted to meet each patient’s individual therapy needs.